Syed Khizer Hasan

List of Publications by Year
in descending order

46	731	623574	552653
papers	citations	14 h-index	26 g-index

47	47	47	1132
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. Blood, 2008, 112, 3383-3390.	0.6	74
2	Understanding the molecular pathogenesis of acute promyelocytic leukemia. Best Practice and Research in Clinical Haematology, 2014, 27, 3-9.	0.7	66
3	Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia. Blood, 2010, 115, 326-330.	0.6	63
4	Acute myeloid leukemia developing in patients with autoimmune diseases. Haematologica, 2012, 97, 805-817.	1.7	63
5	Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML). Leukemia, 2021, 35, 1392-1404.	3.3	51
6	Identification of emerging <scp>FLT</scp>3 <scp>ITD</scp>â€positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosmin. British Journal of Haematology, 2013, 161, 533-540.	1.2	39
7	Risk of acute promyelocytic leukemia in multiple sclerosis. Neurology, 2011, 76, 1059-1065.	1.5	37
8	Analysis of t(15;17) chromosomal breakpoint sequences in therapyâ€related versus de novo acute promyelocytic leukemia: Association of DNA breaks with specific DNA motifs at PML and RARA loci. Genes Chromosomes and Cancer, 2010, 49, 726-732.	1.5	32
9	MOLECULAR PATHOGENESIS OF SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA. Mediterranean Journal of Hematology and Infectious Diseases, 2011, 3, e2011045.	0.5	30
10	Presenting features and treatment outcome of acute promyelocytic leukemia arising after multiple sclerosis. Haematologica, 2011, 96, 621-625.	1.7	23
11	Identification of a potential â€œhotspotâ€•DNA region in the RUNX1 gene targeted by mitoxantrone in therapyâ€related acute myeloid leukemia with t(16;21) translocation. Genes Chromosomes and Cancer, 2009, 48, 213-221.	1.5	22
12	Childhood CML in India: b2a2 transcript is more common than b3a2. Cancer Genetics and Cytogenetics, 2006, 169, 76-77.	1.0	21
13	Inhibition of novel GCN5â€“ATM axis restricts the onset of acquired drug resistance in leukemia. International Journal of Cancer, 2018, 142, 2175-2185.	2.3	18
14	The hidden genomic landscape of acute myeloid leukemia: subclonal structure revealed by undetected mutations. Blood, 2015, 125, 600-605.	0.6	16
15	Early and sensitive detection of PML-A216V mutation by droplet digital PCR in ATO-resistant acute promyelocytic leukemia. Leukemia, 2019, 33, 1527-1530.	3.3	16
16	Comparative molecular analysis of therapy-related and de novo acute promyelocytic leukemia. Leukemia Research, 2012, 36, 474-478.	0.4	15
17	Biology and management of therapy-related acute promyelocytic leukemia. Current Opinion in Oncology, 2013, 25, 695-700.	1.1	15
18	Utility of Immunophenotypic Measurable Residual Disease in Adult Acute Myeloid Leukemiaâ€”Real-World Context. Frontiers in Oncology, 2019, 9, 450.	1.3	14

#	Article	IF	Citations
19	A novel machine-learning-derived genetic score correlates with measurable residual disease and is highly predictive of outcome in acute myeloid leukemia with mutated NPM1. Blood Cancer Journal, 2019, 9, 79.	2.8	13
20	Impact of FLT3 internal tandem duplications on Indian acute promyelocytic leukemia patients: Prognostic implications. Hematology, 2007, 12, 99-101.	0.7	12
21	Two Novel Methods for Rapid Detection and Quantification of DNMT3A R882 Mutations in AcuteÂMyeloid Leukemia. Journal of Molecular Diagnostics, 2015, 17, 179-184.	1.2	9
22	MOLECULAR HETEROGENEITY IN ACUTE PROMYELOCYTIC LEUKEMIA - A SINGLE CENTRE EXPERIENCE FROM INDIA. Mediterranean Journal of Hematology and Infectious Diseases, 2017, 10, 2018002.	0.5	9
23	Exome sequencing study of Russian breast cancer patients suggests a predisposing role for USP39. Breast Cancer Research and Treatment, 2020, 179, 731-742.	1.1	9
24	Long term clinical outcomes of adult hematolymphoid malignancies treated at Tata Memorial Hospital: An institutional audit. Indian Journal of Cancer, 2018, 55, 9.	0.2	9
25	Rapid detection of IDH2 (R140Q and R172K) mutations in acute myeloid leukemia. Annals of Hematology, 2013, 92, 1319-1323.	0.8	8
26	miRNAâ€mRNA Profiling Reveals Prognostic Impact of SMC1A Expression in Acute Myeloid Leukemia. Oncology Research, 2020, 28, 321-330.	0.6	8
27	Acute promyelocytic leukemia with secondary myelofibrosisâ€"Case report and review of the literature. American Journal of Hematology, 2006, 81, 476-477.	2.0	7
28	Longitudinal detection of DNMT3A^{R882H} transcripts in patients with acute myeloid leukemia. American Journal of Hematology, 2018, 93, E120-E123.	2.0	7
29	Clustering of genomic breakpoints at the MLL locus in therapyâ€related acute leukemia with t(4;11)(q21;q23). Genes Chromosomes and Cancer, 2014, 53, 248-254.	1.5	5
30	Studies of proteinâ€"protein interactions in Fanconi anemia pathway to unravel the DNA interstrand crosslink repair mechanism. International Journal of Biological Macromolecules, 2017, 104, 1338-1344.	3.6	5
31	Genetic ablation of pregnancy zone protein promotes breast cancer progression by activating TGF-Î²/SMAD signaling. Breast Cancer Research and Treatment, 2021, 185, 317-330.	1.1	4
32	Over-representation of bcr3 subtype of PML/RARÎ± fusion gene in APL in Indian patients. Annals of Hematology, 2005, 84, 781-784.	0.8	3
33	Genomic analysis of therapyâ€related acute promyelocytic leukemias arising after malignant and nonâ€malignant disorders. American Journal of Hematology, 2014, 89, 346-347.	2.0	2
34	Abstract 4160: PZP as a new gene associated with increased breast cancer risk. , 2019, , .		2
35	Structural and biophysical properties of h-FANCI ARM repeat protein. Journal of Biomolecular Structure and Dynamics, 2017, 35, 3032-3042.	2.0	1
36	Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia and Lymphoma, 2018, 59, 1268-1270.	0.6	1

#	Article	IF	Citations
37	Over expression of brain and acute leukemia, cytoplasmic and ETSâ€related gene is associated with poor outcome in acute myeloid leukemia. Hematological Oncology, 2020, 38, 808-816.	0.8	1
38	Characterization of therapy-related acute leukemia in hereditary breast-ovarian carcinoma patients: role of BRCA1 mutation and topoisomerase II-directed therapy. Medical Oncology, 2020, 37, 48.	1.2	1
39	Timing of allogeneic BMT for CML patients in India: Does it affect response?. American Journal of Hematology, 2007, 82, 329-329.	2.0	0
40	Utilization of Molecular Phenotypes to Detect Relapse and Optimize the Management of Acute Promyelocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, S139-S143.	0.2	0
41	Molecular Characterization of the t(15;17)(q22;21) in Epirubicin-Related Acute Promyelocytic Leukaemia. Blood, 2008, 112, 791-791.	0.6	0
42	Minimal Residual Disease by Multiparametric Flow Cytometry Predicts Relapse Free Survival better than Over-Expression of WT1 and BAALC in Acute Myeloid Leukemia. Blood, 2014, 124, 1064-1064.	0.6	0
43	Abstract 3174: GCN5 regulates ATM mediated DNA repair responsible for onset of acquired resistance in leukemia. , 2017, , .		0
44	Structural characterization of BRCA2 functional domain. Acta Crystallographica Section A: Foundations and Advances, 2017, 73, C1449-C1449.	0.0	0
45	Abstract 4723: Genetic ablation of pregnancy zone protein (PZP) promotes breast cancer progression by activating TGF-Î²/SMAD signalling. , 2020, , .		0
46	Acute promyelocytic leukemia: pathophysiology and clinical results update. , 0, , 131-140.		0